Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05672615 · ClinicalTrials.gov registry record
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
A clinical trial of Non-muscle Invasive Bladder Cancer, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- 42
- Enrollment target
- 1
- Study location
NCT05672615: Recruiting study of Non-muscle Invasive Bladder Cancer, sponsored by Johns Hopkins University.
NCT05672615 is a study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 42 participants, below the 225-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05672615, a study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study. Participation involves providing research blood and urine samples prior to the start of treatment and throughout the treatment course. The study team will also collect participant's medical history and clinical information. Participants will be asked to complete questionnaires and daily mood diaries.
Primary Outcome
Collect urine samples from the patients with non-muscle invasive bladder cancer who are undergoing intravesical instillations for cytokine response to treatment
Conditions Studied
Interventions
- OTHER Questionnaires
- OTHER Daily Mood Diaries
- OTHER Urine Specimen Collection
- OTHER Research Blood Draw
- OTHER Utilize excess tissue from a standard of care procedure
Study Locations (1)
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2028-03 |
What NCT05672615 shows while recruiting
NCT05672615 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 225-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 5 interventions - of which Questionnaires is the first listed.
NCT05672615 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05672615 about?
NCT05672615 is a clinical study titled "Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG". The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study. Partic...
What is the current status of trial NCT05672615?
This trial is currently recruiting. The enrollment target is 42 participants. The study started on 2023-03-21. Estimated completion is 2028-03.
What conditions does trial NCT05672615 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
What interventions are being tested in trial NCT05672615?
The interventions under investigation include: Questionnaires (OTHER), Daily Mood Diaries (OTHER), Urine Specimen Collection (OTHER), Research Blood Draw (OTHER), Utilize excess tissue from a standard of care procedure (OTHER).
Who is sponsoring clinical trial NCT05672615?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05672615 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05672615's enrollment target sits among peer trials
42 22nd of 30 higher than 9 of 30 other Non-muscle Invasive Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-muscle Invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
RECRUITING · Phase 2
-
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI